drugset / Trial / NCT00799149

Etoricoxib Versus Gabapentin for Knee Arthroscopy

NCT00799149

Phase 4 Completed 75 enrolled Meir Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine that when administered as part of a multimodal analgesic regimen, use of the new COX-2 antagonist etoricoxib (120 mg/day, per os) is more effective in improving postoperative pain management after knee arthroscopy than gabapentin (1.2 g/day, per os).

Timeline

Start
2006-06
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Etoricoxib Small molecule 120 mg Oral
Comparator Gabapentin Small molecule 1200 mg Oral

Indications

No indication recorded.